Announcements Trials
Browse Landscape

Phase

Phase 2 37Phase 1 24Phase 1/2 18Phase 3 12Phase 2/3 4Phase EARLY_PHASE1 2Phase 4 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Letrozole 6Tamoxifen 4Cisplatin 4Anastrozole 4ribociclib 3exemestane 3Vancomycin 3Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Carboplatin 3Bevacizumab 3trametinib 2toripalimab 2encorafenib 2dabrafenib 2binimetinib 2atezolizumab 2asciminib 2Vincristine 2Sodium Chloride 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Methotrexate 2Medroxyprogesterone Acetate 2Lenalidomide 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Azacitidine × 90 days × Clear all
NCT06370000 2026-05-29

REMAIN1

Virginia Commonwealth University

Phase 4 Recruiting
12 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07044687 2026-05-12

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

AbbVie

Phase 4 Recruiting
100 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡